in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
.u.s.
.. a little under 60% of these encounters resulted in hospitalization and of these, about 13% required intensive care.
.
.
u.s.
.. a little under 60% of these encounters resulted in hospitalization and of these, about 13% required intensive care.
.
.
.